Compugen医疗 CGEN 深 沪
等待开盘 05-19 09:30:00 美东时间
2.86
+0.110
+4.00%
华盛通- 最 高3.015
- 今 开2.84
- 成交量 170.41万股
- 最 低 2.69
- 昨 收 2.75
- 总市值 2.70亿
- 52周最高 3.235
- 市盈率 静 7.59
- 换手率 1.80%
- 52周最低 1.295
- 委 比 -23.43%
- 总股本 9455.41万
- 历史最高 19.90
- 量 比 3.40
- 振 幅 11.82%
- 历史最低 0.51
- 每 手 1
- 风险率 0.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For May 18, 2026
Companies Reporting Before The Bell • Compugen (NASDAQ:CGEN) is likely to repor...
05-18 19:11
Compugen Q1 EPS $(0.08) Misses $(0.07) Estimate, Sales $2.176M Beat $2.095M Estimate
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 14.29 percent. This is unchanged from the same period last year. The company reported
05-18 19:01
Compugen Reports First Quarter 2026 Results
COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the U.S., Israel, and France; interim analysis on track by Q1 2027 Partner AstraZeneca is advancing rilvego...
05-18 19:00
Compugen Q1 2026 Earnings Preview
Compugen (CGEN) is scheduled to announce Q1 earnings results on Monday, May 18th, after market close. The consensus EPS Estimate is -$0.08 (flat Y/Y) and the consensus Revenue Estimate is $1.26M (-45....
05-18 05:35
Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum
HOLON, Israel, May 12, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by...
05-12 19:00
Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference
HOLON, Israel, April 9, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today an...
04-09 19:00
美股大行评级 | 高盛首予PayPay“买入”评级；神经分泌生物科学获花旗等多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从13美元升至20美元；韦德布什：维持FuboTV"跑赢大市"评级，目标价从3.5美元升至24美元
04-08 18:35
Lake Street Initiates Coverage On Compugen with Buy Rating, Announces Price Target of $6
Lake Street analyst Chad Messer initiates coverage on Compugen (NASDAQ:CGEN) with a Buy rating and announces Price Target of $6.
04-07 20:40
Compugen Ltd. Director Sanford S. Zweifach Files Initial Beneficial Ownership Statement
Compugen Ltd. Director Sanford S. Zweifach Files Initial Beneficial Ownership Statement Sanford Zweifach filed an initial statement of beneficial ownership as a director of Compugen. The filing reported 12,680 ordinary shares beneficially owned directly. It also reported share options covering 10,00
03-18 18:33
Compugen Ltd. director Gilead Halevy files initial beneficial ownership statement
Compugen Ltd. director Gilead Halevy files initial beneficial ownership statement Gilead Halevy filed an initial statement of beneficial ownership for Compugen in connection with his role as a director. The filing reported direct ownership of 11,407 ordinary shares. It also listed share options to b
03-18 18:07
